Extrapyramidal Syndromes: PET and SPECT

Neuroimaging Clinics of North America

Volumn 20, Issue 1, 2010, Pages 57-68

  Tatsch, Klaus ^a  

^a Karlsruhe City Hospital   (Germany)

Author keywords

Differential diagnosis; Dopaminergic system; Glucose metabolism; Parkinsonism; PET SPECT; Sympathetic innervation

Indexed keywords

LEVODOPA;

ALZHEIMER DISEASE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL PRACTICE; CORTICOBASAL DEGENERATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DOPAMINERGIC SYSTEM; EARLY DIAGNOSIS; EXTRAPYRAMIDAL SYMPTOM; GLUCOSE METABOLISM; HUMAN; HUNTINGTON CHOREA; IMAGE ANALYSIS; MOLECULAR IMAGING; NEUROIMAGING; PARKINSON DISEASE; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW; SENSITIVITY AND SPECIFICITY; SHY DRAGER SYNDROME; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPINOCEREBELLAR DEGENERATION; SYMPATHETIC INNERVATION; VASCULAR PARKINSONISM; WILSON DISEASE;

BASAL GANGLIA DISEASES; BRAIN; NEURODEGENERATIVE DISEASES; PARKINSONIAN DISORDERS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 70549105116     PISSN: 10525149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nic.2009.08.017     Document Type: Review

References (95)

1. Leitlinie: Parkinson-syndrome: diagnostik und therapie. überarbeitete Auflage. Leitlinien für diagnostik und therapie in der neurologie. 4th edition (2008), Georg Thieme Verlag, Stuttgart
2. Catafau A.M., and Tolosa E. Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord 19 (2004) 1175-1182
3. Hughes A.J., Ben-Shlomo Y., Daniel S.E., et al. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. 1992. Neurology 57 (2001) S34-S38
4. Hughes A.J., Daniel S.E., Kilford L., et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatr 55 (1992) 181-184
5. Marshall V.L., Reininger C.B., Marquardt M., et al. Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord 24 (2009) 500-508
6. McKeith I., Mintzer J., Aarsland D., et al. Dementia with Lewy bodies. Lancet Neurol 3 (2004) 19-28
7. Meara J., Bhowmick B.K., and Hobson P. Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Ageing 28 (1999) 99-102
8. Booij J., Tissingh G., Winogrodzka A., et al. Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med 26 (1999) 171-182
9. Brooks D.J. Assessment of Parkinson's disease with imaging. Parkinsonism Relat Disord 13 Suppl 3 (2007) S268-S275
10. Brooks D.J. Neuroimaging in Parkinson's disease. NeuroRx 1 (2004) 243-254
11. Brucke T., Djamshidian S., Bencsits G., et al. SPECT and PET imaging of the dopaminergic system in Parkinson's disease. J Neurol 247 Suppl 4 (2000) IV/2-IV/7
12. Marshall V., and Grosset D. Role of dopamine transporter imaging in routine clinical practice. Mov Disord 18 (2003) 1415-1425
13. Nikolaus S., Antke C., Kley K., et al. Investigating the dopaminergic synapse in vivo. I. Molecular imaging studies in humans. Rev Neurosci 18 (2007) 439-472
14. Scherfler C., Schwarz J., Antonini A., et al. Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov Disord 22 (2007) 1229-1238
15. Tatsch K. Imaging of the dopaminergic system in parkinsonism with SPET. Nucl Med Commun 22 (2001) 819-827
16. Frey K.A., Koeppe R.A., and Kilbourn M.R. Imaging the vesicular monoamine transporter. Adv Neurol 86 (2001) 237-247
17. Eckert T., Barnes A., Dhawan V., et al. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 26 (2005) 912-921
18. Post K.K., Singer C., and Papapetropoulos S. Cardiac denervation and dysautonomia in Parkinson's disease: a review of screening techniques. Parkinsonism Relat Disord 14 (2008) 524-531
19. Raffel D.M., Koeppe R.A., Little R., et al. PET measurement of cardiac and nigrostriatal denervation in Parkinsonian syndromes. J Nucl Med 47 (2006) 1769-1777
20. Rinne J.O., Ruottinen H., Bergman J., et al. Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease. J Neurol Neurosurg Psychiatr 67 (1999) 737-741
21. Seibyl J.P., Marek K.L., Quinlan D., et al. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 38 (1995) 589-598
22. Tatsch K., Schwarz J., Mozley P.D., et al. Relationship between clinical features of Parkinson's disease and presynaptic dopamine transporter binding assessed with [123I]IPT and single-photon emission tomography. Eur J Nucl Med 24 (1997) 415-421
23. Brooks D.J. Morphological and functional imaging studies on the diagnosis and progression of Parkinson's disease. J Neurol 247 Suppl 2 (2000) II11-II18
24. Marek K.L., Seibyl J.P., Zoghbi S.S., et al. [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 46 (1996) 231-237
25. Winogrodzka A., Bergmans P., Booij J., et al. [(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease. J Neurol Neurosurg Psychiatr 74 (2003) 294-298
26. Berendse H.W., Booij J., Francot C.M., et al. Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell. Ann Neurol 50 (2001) 34-41
27. Khan N.L., Brooks D.J., Pavese N., et al. Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. Brain 125 Pt 10 (2002) 2248-2256
28. Laihinen A., Ruottinen H., Rinne J.O., et al. Risk for Parkinson's disease: twin studies for the detection of asymptomatic subjects using [18F]6-fluorodopa PET. J Neurol 247 Suppl 2 (2000) II110-II113
29. Piccini P., Morrish P.K., Turjanski N., et al. Dopaminergic function in familial Parkinson's disease: a clinical and 18F-dopa positron emission tomography study. Ann Neurol 41 (1997) 222-229
30. Wolters E.C., Francot C., Bergmans P., et al. Preclinical (premotor) Parkinson's disease. J Neurol 247 Suppl 2 (2000) II103-II109
31. Morrish P.K., Rakshi J.S., Bailey D.L., et al. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatr 64 (1998) 314-319
32. Nurmi E., Bergman J., Eskola O., et al. Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F]CFT PET. Synapse 48 (2003) 109-115
33. Nurmi E., Ruottinen H.M., Bergman J., et al. Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study. Mov Disord 16 (2001) 608-615
34. Schwarz J., Storch A., Koch W., et al. Loss of dopamine transporter binding in Parkinson's disease follows a single exponential rather than linear decline. J Nucl Med 45 (2004) 1694-1697
35. Stoffers D., Booij J., Bosscher L., et al. Early-stage [123I]beta-CIT SPECT and long-term clinical follow-up in patients with an initial diagnosis of Parkinson's disease. Eur J Nucl Med Mol Imaging 32 (2005) 689-695
36. Pirker W., Djamshidian S., Asenbaum S., et al. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study. Mov Disord 17 (2002) 45-53
37. Pirker W., Holler I., Gerschlager W., et al. Measuring the rate of progression of Parkinson's disease over a 5-year period with beta-CIT SPECT. Mov Disord 18 (2003) 1266-1272
38. Fahn S., Oakes D., Shoulson I., et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 351 (2004) 2498-2508
39. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287 (2002) 1653-1661
40. Whone A.L., Watts R.L., Stoessl A.J., et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 54 (2003) 93-101
41. Marek K., Jennings D., and Seibyl J. Dopamine agonists and Parkinson's disease progression: what can we learn from neuroimaging studies. Ann Neurol 53 Suppl 3 (2003) S160-S166 [discussion: S166-9]
42. Morrish P.K. How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease?. Mov Disord 18 Suppl 7 (2003) S63-S70
43. Seibyl J., Jennings D., Tabamo R., et al. Unique roles of SPET brain imaging in clinical and research studies. Lessons from Parkinson's disease research. Q J Nucl Med Mol Imaging 49 (2005) 215-221
44. Brucke T., Asenbaum S., Pirker W., et al. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl 50 (1997) 9-24
45. Pirker W., Asenbaum S., Bencsits G., et al. [123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord 15 (2000) 1158-1167
46. Pirker W., Asenbaum S., Wenger S., et al. Iodine-123-epidepride-SPECT: studies in Parkinson's disease, multiple system atrophy and Huntington's disease. J Nucl Med 38 (1997) 1711-1717
47. Varrone A., Marek K.L., Jennings D., et al. [(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy. Mov Disord 16 (2001) 1023-1032
48. Seppi K., Scherfler C., Donnemiller E., et al. Topography of dopamine transporter availability in progressive supranuclear palsy: a voxelwise [123I]beta-CIT SPECT analysis. Arch Neurol 63 (2006) 1154-1160
49. Klaffke S., Kuhn A.A., Plotkin M., et al. Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degeneration. Mov Disord 21 (2006) 1724-1727
50. Laureys S., Salmon E., Garraux G., et al. Fluorodopa uptake and glucose metabolism in early stages of corticobasal degeneration. J Neurol 246 (1999) 1151-1158
51. Boesch S.M., Donnemiller E., Muller J., et al. Abnormalities of dopaminergic neurotransmission in SCA2: a combined 123I-betaCIT and 123I-IBZM SPECT study. Mov Disord 19 (2004) 1320-1325
52. Varrone A., Salvatore E., De Michele G., et al. Reduced striatal [123 I]FP-CIT binding in SCA2 patients without parkinsonism. Ann Neurol 55 (2004) 426-430
53. Wang P.S., Liu R.S., Yang B.H., et al. Regional patterns of cerebral glucose metabolism in spinocerebellar ataxia type 2, 3 and 6: a voxel-based FDG-positron emission tomography analysis. J Neurol 254 (2007) 838-845
54. Wullner U., Reimold M., Abele M., et al. Dopamine transporter positron emission tomography in spinocerebellar ataxias type 1, 2, 3, and 6. Arch Neurol 62 (2005) 1280-1285
55. Reimold M., Globas C., Gleichmann M., et al. Spinocerebellar ataxia type 1, 2, and 3 and restless legs syndrome: striatal dopamine D2 receptor status investigated by [11C]raclopride positron emission tomography. Mov Disord 21 (2006) 1667-1673
56. Andrews T.C., and Brooks D.J. Advances in the understanding of early Huntington's disease using the functional imaging techniques of PET and SPET. Mol Med Today 4 (1998) 532-539
57. Boecker H., Kuwert T., Langen K.J., et al. SPECT with HMPAO compared to PET with FDG in Huntington disease. J Comput Assist Tomogr 18 (1994) 542-548
58. Ichise M., Toyama H., Fornazzari L., et al. Iodine-123-IBZM dopamine D2 receptor and technetium-99m-HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington's disease. J Nucl Med 34 (1993) 1274-1281
59. Leblhuber F., Brucker B., Reisecker F., et al. Single photon emission computed tomography in subjects at risk for Huntington's chorea. J Neurol 237 (1990) 496-498
60. Leblhuber F., Hoell K., Reisecker F., et al. Single photon emission computed tomography in Huntington's chorea. Psychiatry Res 29 (1989) 337-339
61. Leslie W.D., Greenberg C.R., Abrams D.N., et al. Clinical deficits in Huntington disease correlate with reduced striatal uptake on iodine-123 epidepride single-photon emission tomography. Eur J Nucl Med 26 (1999) 1458-1464
62. Barthel H., Hermann W., Kluge R., et al. Concordant pre- and postsynaptic deficits of dopaminergic neurotransmission in neurologic Wilson disease. AJNR Am J Neuroradiol 24 (2003) 234-238
63. Jeon B., Kim J.M., Jeong J.M., et al. Dopamine transporter imaging with [123I]-beta-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson's disease. J Neurol Neurosurg Psychiatr 65 (1998) 60-64
64. Oder W., Brucke T., Kollegger H., et al. Dopamine D2 receptor binding is reduced in Wilson's disease: correlation of neurological deficits with striatal 123I-iodobenzamide binding. J Neural Transm 103 (1996) 1093-1103
65. Oertel W.H., Tatsch K., Schwarz J., et al. Decrease of D2 receptors indicated by 123I-iodobenzamide single-photon emission computed tomography relates to neurological deficit in treated Wilson's disease. Ann Neurol 32 (1992) 743-748
66. Tatsch K., Schwarz J., Oertel W.H., et al. SPECT imaging of dopamine D2 receptors with 123I-IBZM: initial experience in controls and patients with Parkinson's syndrome and Wilson's disease. Nucl Med Commun 12 (1991) 699-707
67. Wang P., Hu P., Yue D.C., et al. The clinical value of Tc-99m TRODAT-1 SPECT for evaluating disease severity in young patients with symptomatic and asymptomatic Wilson disease. Clin Nucl Med 32 (2007) 844-849
68. Koch W., Hamann C., Radau P.E., et al. Does combined imaging of the pre- and postsynaptic dopaminergic system increase the diagnostic accuracy in the differential diagnosis of parkinsonism?. Eur J Nucl Med Mol Imaging 34 (2007) 1265-1273
69. Tatsch K., Wängler B., Bötzel K., et al. Differential diagnosis of parkinsonism with [F-18]DMFP PET. J Nucl Med 49 Suppl 1 (2008) 5P
70. Nagayama H., Hamamoto M., Ueda M., et al. Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease. J Neurol Neurosurg Psychiatr 76 (2005) 249-251
71. Saiki S., Hirose G., Sakai K., et al. Cardiac 123I-MIBG scintigraphy can assess the disease severity and phenotype of PD. J Neurol Sci 220 (2004) 105-177
72. Sawada H., Oeda T., Yamamoto K., et al. Diagnostic accuracy of cardiac metaiodobenzylguanidine scintigraphy in Parkinson disease. Eur J Neurol 16 (2009) 174-182
73. Spiegel J., Hellwig D., Farmakis G., et al. Myocardial sympathetic degeneration correlates with clinical phenotype of Parkinson's disease. Mov Disord 22 (2007) 1004-1008
74. Spiegel J., Mollers M.O., Jost W.H., et al. FP-CIT and MIBG scintigraphy in early Parkinson's disease. Mov Disord 20 (2005) 552-561
75. Van Laere K., Casteels C., De Ceuninck L., et al. Dual-tracer dopamine transporter and perfusion SPECT in differential diagnosis of parkinsonism using template-based discriminant analysis. J Nucl Med 47 (2006) 384-392
76. Asenbaum S., Pirker W., Angelberger P., et al. [123I]beta-CIT and SPECT in essential tremor and Parkinson's disease. J Neural Transm 105 (1998) 1213-1228
77. Benamer T.S., Patterson J., Grosset D.G., et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 15 (2000) 503-510
78. Booij J., Speelman J.D., Horstink M.W., et al. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 28 (2001) 266-272
79. Huang C.C., Yen T.C., Weng Y.H., et al. Normal dopamine transporter binding in dopa responsive dystonia. J Neurol 249 (2002) 1016-1020
80. Jeon B.S., Jeong J.M., Park S.S., et al. Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia. Ann Neurol 43 (1998) 792-800
81. Zijlmans J.C., Daniel S.E., Hughes A.J., et al. Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Mov Disord 19 (2004) 630-640
82. Gerschlager W., Bencsits G., Pirker W., et al. [123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease. Mov Disord 17 (2002) 518-523
83. Tatsch K. Imaging of the dopaminergic system in differential diagnosis of dementia. Eur J Nucl Med Mol Imaging 35 Suppl 1 (2008) S51-S57
84. Herholz K., Carter S.F., and Jones M. Positron emission tomography imaging in dementia. Br J Radiol 80 Spec No 2 (2007) S160-S167
85. Silverman D.H. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med 45 (2004) 594-607
86. Van Heertum R.L., and Tikofsky R.S. Positron emission tomography and single-photon emission computed tomography brain imaging in the evaluation of dementia. Semin Nucl Med 33 (2003) 77-85
87. Piggott M.A., Marshall E.F., Thomas N., et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain 122 Pt 8 (1999) 1449-1468
88. Suzuki M., Desmond T.J., Albin R.L., et al. Striatal monoaminergic terminals in Lewy body and Alzheimer's dementias. Ann Neurol 51 (2002) 767-771
89. Koeppe R.A., Gilman S., Junck L., et al. Differentiating Alzheimer's disease from dementia with Lewy bodies and Parkinson's disease with (+)-[11C]dihydrotetrabenazine positron emission tomography. Alzheimers Dement 4 1 Suppl 1 (2008) S67-S76
90. O'Brien J.T., Colloby S., Fenwick J., et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 61 (2004) 919-925
91. Walker Z., Costa D.C., Walker R.W., et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatr 73 (2002) 134-140
92. McKeith I., O'Brien J., Walker Z., et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 6 (2007) 305-313
93. Walker Z., Costa D.C., Walker R.W., et al. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison. Neurology 62 (2004) 1568-1572
94. Walker Z., Jaros E., Walker R.W., et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatr 78 (2007) 1176-1181
95. Koeppe R.A., Gilman S., Joshi A., et al. 11C-DTBZ and 18F-FDG PET measures in differentiating dementias. J Nucl Med 46 (2005) 936-944